Abiopharma

🔍 Casdin Partners Master Fund, L.P. (Director)

Company: STANDARD BIOTOOLS INC. (LAB)

Report Date: 2025-09-03

Detailed Transactions and Holdings:

• Acquired 250,000 shares of Common Stock, $0.001 par value per share at $1.2656 per share (Direct)
  Date: 2025-09-03 | Code: P | equity_swap_involved: 0 | shares_owned_after: 60,525,000.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 250,000 shares of Common Stock, $0.001 par value per share at $1.2774 per share (Direct)
  Date: 2025-09-04 | Code: P | equity_swap_involved: 0 | shares_owned_after: 60,775,000.00 | transaction_form_type: 4 | Footnotes: F3, F2
• Holds 0 shares of Common Stock, $0.001 par value per share (Direct)
  Date: 2025-09-03 | Code: H | shares_owned_after: 2,901,062.00 | Footnotes: F4
• Holds 0 shares of Common Stock, $0.001 par value per share (Direct)
  Date: 2025-09-03 | Code: H | nature_of_ownership: See footnote | shares_owned_after: 13,939,637.00 | Footnotes: F5
• Holds 0 shares of Common Stock, $0.001 par value per share (Direct)
  Date: 2025-09-03 | Code: H | nature_of_ownership: See footnote | shares_owned_after: 2,744,219.00 | Footnotes: F6

Footnotes:

• F1: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.2414 to $1.2765. The Reporting Persons undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.
• F2: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP.
• F3: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.2621 to $1.2930. The Reporting Persons undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.
• F4: The securities are owned directly by Eli Casdin.
• F5: The securities are owned directly by Casdin Private Growth Equity Fund II, L.P. (the "Equity Fund II") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund II, and (ii) Eli Casdin, the managing member of Casdin.
• F6: The securities are owned directly by Casdin Private Growth Equity Fund, L.P. (the "Equity Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund, and (ii) Eli Casdin, the managing member of Casdin.
• REMARKS: Eli Casdin has been deputized to represent the Reporting Persons on the board of directors of the Issuer. By virtue of Mr. Casdin's representation, for purposes of Section 16 of the Securities Exchange Act of 1934 (the "Exchange Act"), each of the Reporting Persons may be deemed directors by deputization of the Issuer. Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.